Life Sciences

  • March 31, 2026

    Biogen Paying $5.6B For Apellis As 4 Firms Advise

    Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders. 

  • March 31, 2026

    Beasley Allen Seeks Stay Of DQ In Federal J&J Talc MDL

    The Beasley Allen Law Firm asked a New Jersey federal court on Monday to hold off on disqualifying it from talc litigation against Johnson & Johnson while it appeals the disqualification order which it called "unprecedented and incorrect."

  • March 31, 2026

    Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim

    A Liberty Mutual unit accused Yale University's health system of making "serious and material misstatements" about a plan member's bone marrow transplant, the insurer said in its answer and counterclaim for a declaratory judgment that it can continue to deny the $4.1 million claim.

  • March 31, 2026

    Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal

    Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, announced plans Tuesday to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.

  • March 31, 2026

    Cancer Vaccine Developer Files Ch. 7 After Trials Fall Short

    A Denmark-based biotechnology firm filed for Chapter 7 liquidation Tuesday in Delaware with more than $10 million in debt after its prospective cancer vaccine failed to measure up under testing and win regulatory approval last year.

  • March 30, 2026

    Don't Set Special IP Rules For 'Skinny Labels,' Justices Told

    Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.

  • March 30, 2026

    FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices

    The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs. 

  • March 30, 2026

    Sanofi Claims IP Life Extension Needed For Double Patenting

    The Patent Trial and Appeal Board rightly found a Sanofi patent application shouldn't be rejected for obviousness-type double patenting, as it doesn't improperly extend patent life, the French drugmaker and its allies have told U.S. Patent and Trademark Office Director John Squires.

  • March 30, 2026

    Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund

    Private equity giant Blackstone, led by Cleary Gottlieb Steen & Hamilton LLP, revealed Monday that it wrapped its sixth life sciences fund after securing $6.3 billion of capital commitments, marking what the firm says is the largest private life sciences fund ever raised.

  • March 30, 2026

    Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push

    Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by pharmaceutical giants seeking accelerated paths to new treatments. 

  • March 30, 2026

    Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud

    A Delaware federal judge has affirmed a $34 million verdict against Alcon and related entities for infringing patents covering medical devices to treat glaucoma, disagreeing that Sight Sciences Inc. had failed to show the accused product meets the limitations of the patent claims.

  • March 30, 2026

    J&J Unit Wants Forensic Exam Of Ex-Director's Devices

    A Johnson & Johnson subsidiary urged a New Jersey federal court to order a former associate director to submit to a court-supervised forensic inspection of any device or account in which she could have stored confidential information it claims she downloaded in order to start her own competing company.

  • March 30, 2026

    Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims

    Eagle Pharmaceuticals Inc. and its former executives have agreed to pay $9.5 million to settle investor claims that they carried out a fraudulent "channel stuffing" scheme to inflate the revenue of one of the company's brand-name medications.

  • March 30, 2026

    High Court Turns Away CRISPR Patent Validity Dispute

    The U.S. Supreme Court on Monday rejected Agilent Technologies' bid to revive patents on the gene-editing tool CRISPR, which centers on the burden of proof in establishing prior art.

  • March 30, 2026

    Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud

    The U.S. Supreme Court rejected on Monday a former Quest Diagnostics Inc. compliance officer's bid for review of the dismissal of a long-running False Claims Act suit against the medical testing company.

  • March 30, 2026

    Justices Reject TM Appeal Tied To 'Use In Commerce'

    The U.S. Supreme Court on Monday declined to take up an appeal challenging a Ninth Circuit ruling that upheld a multimillion-dollar default judgment based largely on statements defendants made in trademark applications.

  • March 27, 2026

    Elizabeth Holmes Gets 11-Year Prison Sentence Cut By A Year

    A California federal judge has shaved off a year from convicted ex-Theranos CEO Elizabeth Holmes' 11-year-and-three-month prison sentence for securities fraud due to recent sentencing guideline amendments, reducing her time behind bars by one year, instead of the two years she requested, amid objections by prosecutors.

  • March 27, 2026

    Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive

    A California federal judge has refused to throw out a lawsuit accusing a pair of telehealth companies of making copies of Eli Lilly's obesity and type 2 diabetes drugs but agreed to trim the case.

  • March 27, 2026

    Del. Justices Won't Revive Hedge Fund Insider Trading Case

    The Delaware Supreme Court upheld a ruling Friday in favor of hedge fund Armistice Capital, backing the dismissal of a lawsuit accusing the firm of insider trading on information it had obtained in its position as a minority stakeholder of a pharmaceutical company.

  • March 27, 2026

    Hospital System Beats Most Of REIT's $50M Floodwall Suit

    A New York federal judge on March 27 mostly tossed a real estate investment trust's $50 million suit against the New York City Health and Hospitals Corp. and the NYC Economic Development Corp. over the design of a proposed floodwall for a downtown Manhattan life sciences campus project.

  • March 27, 2026

    Nobel Prize Winners Again Lose Patent Fight Over CRISPR

    The Patent Trial and Appeal Board has ruled against a pair of Nobel Prize-winning scientists in a patent dispute over who was the first to invent key aspects of the gene-editing technology CRISPR, siding again with a rival team from the Broad Institute and the Massachusetts Institute of Technology.

  • March 27, 2026

    Skincare Co. Says ITC Ruling Backs Ending PTAB Challenge

    Skin products company Hydrafacial has argued U.S. Patent and Trademark Office Director John Squires should turn down a rehearing request from rival Sinclair Pharma over Squires' order de-instituting a challenge to Hydrafacial's patent, saying a U.S. International Trade Commission decision upholding the same patent supports the director's move.

  • March 27, 2026

    Sens. Push Bill To Equip VA For Psychedelic Therapies

    A bipartisan group of U.S. senators has introduced legislation to broaden veterans' access to emerging therapies, including psychedelic-assisted treatments, that may be effective in addressing post-traumatic stress disorder and other mental health issues.

  • March 27, 2026

    Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says

    Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while hiding unpredictable placebo responses and other known risks, before the phase ultimately failed, causing a stock price collapse. 

  • March 27, 2026

    Biogen Beats Investor Suit Over Dozens Of Drug Claims

    Biogen Inc. and four of its executives escaped a stock drop suit Friday after a Massachusetts federal judge ruled that none of the nearly five dozen statements challenged by investors suggested that the company intentionally misled people buying its stock.

Expert Analysis

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

  • AI Product Safety Insights May Expand Foreseeability

    Author Photo

    Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.

  • Series

    Law School's Missed Lessons: Educating Your Community

    Author Photo

    Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Adapting To USPTO's Reduction Of Examiner Interview Time

    Author Photo

    Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • 5 Crisis Lawyering Skills For An Age Of Uncertainty

    Author Photo

    As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.

  • Anticipating FTC's Shift On Unfair Competition Enforcement

    Author Photo

    As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University.

  • Insights From Recent Cases On Navigating Snap Removal

    Author Photo

    Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.

  • Opinion

    It's Time For The Judiciary To Fix Its Cybersecurity Problem

    Author Photo

    After recent reports that hackers have once again infiltrated federal courts’ electronic case management systems, the judiciary should strengthen its cybersecurity practices in line with executive branch standards, outlining clear roles and responsibilities for execution, says Ilona Cohen at HackerOne.

  • Series

    Writing Novels Makes Me A Better Lawyer

    Author Photo

    Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler.

  • SDNY OpenAI Order Clarifies Preservation Standards For AI

    Author Photo

    The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.

  • What 9th Circ.'s Rosenwald Ruling Means For Class Actions

    Author Photo

    The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.